- Menlo Therapeutics (MNLO -4.2%) announces that "one of the largest" U.S. insurers has added Amzeeq (minocycline) topical foam, 4% to its formulary for the treatment of acne vulgaris in patients as young as nine years old.
- CEO David Domzalski says, “We are pleased with the continued expansion of our national coverage for Amzeeq. With this additional plan under contract, we now have coverage for up to 60% of the total commercial lives in the United States.”
Menlo expands insurance coverage of acne foam Amzeeq
Recommended For You
More Trending News
About VYNE Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
VYNE | - | - |
VYNE Therapeutics Inc. |